CONSOLIDATED STATEMENTS OF STOCKHOLDER'S DEFICIT (USD $)	Series A Preferred	Common Stock	Additional Paid-In Capital	Treasury Stock	Notes Receivable from Sale of Stock	Deficit Accumulated During the Development Stage	Total
Beginning Balance, Amount at May. 26, 1998
Beginning Balance, Shares at May. 26, 1998
Fair value of common stock issued for services, Amount		400	359,400				359,800
Fair value of common stock issued for services, Shares		403,375
Effect of the Merger, Amount		1,600	(1,600)
Effect of the Merger, Shares		1,569,000
Sale of common stock for cash, Amount		1,200	24,900				26,100
Sale of common stock for cash, Shares		1,211,086
Fair value of warrants issued for services			481,700				481,700
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount		400	314,900		(149,800)		165,500
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		4,110,863
Share-based compensation expense			2,763,000				2,763,000
Forgiveness of accrued compensation and accrued interest payable to officers			799,900				799,900
Proceeds allocated to warrants issued in connection with Platinum Notes			1,059,100				1,059,100
Accrued interest on notes receivable					(34,300)		(34,300)
Effect of reverse stock split		(6)
Cumulative effect of adopting new accounting standard			(293,700)			142,300	(151,400)
Common stock issued for cancellation of accounts payable and accrued interest, Amount		1,600	2,468,600				2,470,200
Common stock issued for cancellation of accounts payable and accrued interest, Shares		1,646,792
Incremental fair value of note conversion options from debt modification			1,891,200				1,891,200
Net Loss						(42,715,300)	(42,715,300)
Ending Balance, Amount at Mar. 31, 2011		5,200	9,867,400		(184,100)	(42,573,000)	(32,884,500)
Ending Balance, Shares at Mar. 31, 2011		5,241,110
Fair value of warrants issued for services			564,500				564,500
Share-based compensation expense			1,591,300				1,591,300
Accrued interest on notes receivable					(1,000)		(1,000)
Reclassification of warrant liability to equity			424,100				424,100
Incremental value of Platinum note modification			1,070,600				1,070,600
Incremental value of Morrison Foerster warrant modification			58,700				58,700
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Amount		2,200	3,674,000		(500,000)		3,176,200
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Shares		2,216,106
Payments on note receivable for sale of stock					250,000		250,000
Stock issued upon conversion of convertible promissory notes, Amount		3,500	6,171,300				6,174,800
Stock issued upon conversion of convertible promissory notes, Shares		3,528,290
Stock issued upon conversion of all series of preferred stock, Amount		2,900	14,531,900				14,534,800
Stock issued upon conversion of all series of preferred stock, Shares		2,884,655
Fair value of stock issued for services prior to the Merger, Amount		1,400	2,224,100				2,225,500
Fair value of stock issued for services prior to the Merger, Shares		1,371,743
Forgiveness of notes at the Merger, Amount					185,100		185,100
Stock issued upon exercise of modified warrants (includes Platinum exercises), Amount		3,100	3,426,200				3,429,300
Stock issued upon exercise of modified warrants (includes Platinum exercises), Shares		3,121,259
Incremental value of warrant modifications (including modification of Platinum warrants)			1,028,900				1,028,900
Fair value of bonus warrants under Discounted Warrant Exercise Program			138,100				138,100
Stock issued in Fall 2011 Follow-on Offering, Amount		100	111,200				111,300
Stock issued in Fall 2011 Follow-on Offering, Shares		63,570
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount		100	102,100				102,200
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		113,979
Fair value of stock issued for services following the Merger, Amount		200	451,800				452,000
Fair value of stock issued for services following the Merger, Shares		155,555
Proceeds allocated to warrants issued and beneficial conversion feature in connection with 12% convertible notes			461,700				461,700
Stock issued in connection with note term extension, Amount			22,400				22,400
Stock issued in connection with note term extension, Shares		8,000
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Amount	200		3,387,700				3,387,900
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Shares	231,090
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Amount			750,600	(750,600)
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Shares	45,980
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Amount	200		2,480,900	(2,481,100)
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Shares	159,985
Net Loss						(12,209,500)	(12,209,500)
Ending Balance, Amount at Mar. 31, 2012	400	18,700	52,539,500	(3,231,700)	(250,000)	(54,782,500)	(5,705,600)
Ending Balance, Shares at Mar. 31, 2012	437,055	18,704,267
Fair value of common stock issued for services, Amount		400	339,600				340,000
Fair value of common stock issued for services, Shares		400,000
Fair value of warrants issued for services			106,200				106,200
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount		500	274,000				274,500
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares		549,056
Share-based compensation expense			1,241,300				1,241,300
Incremental fair value of note conversion options from debt modification			440,700				440,700
Incremental value of Morrison Foerster warrant modification			998,500				998,500
Payments on note receivable for sale of stock					66,900		66,900
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Amount	100		736,300	(736,400)
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Shares	62,945
Fair value of warrants issued upon exercise of modified warrants			35,900				35,900
Fair value of shares issued in settlement of accounts payable, amount		100	103,100				103,200
Fair value of shares issued in settlement of accounts payable, shares		103,235
Modification of note receivable from sale of stock					(26,000)		(26,000)
Fair value of warrant issued to Cato Holding Company in connection with note payable restructure			120,500				120,500
Fair value of warrant issued to Cato Holding Company in connection with accounts payable restructure			486,200				486,200
Fair value of warrant issued to University Health Network in connection with accounts payable restructure			998,500				998,500
Fair value of warrants issued to Morrison & Foerster, Cato Reearch Ltd. and University Health Network in connection with accrued interest on underlying notes			49,400				49,400
Sale of Units in Winter 2012 Private Placement, net, Amount		2,400	1,246,600				1,249,000
Sale of Units in Winter 2012 Private Placement, net, Shares		2,366,330
Exchange of February 2012 convertible notes, Amount		1,400	1,214,200				1,215,600
Exchange of February 2012 convertible notes, Shares		1,357,281
Fair value of warrants issued to banker in connection with exchange of February 2012 convertible notes			28,200				28,200
Premium of fair value over face value of Exchange Note issued to Platinum			1,083,200				1,083,200
Fair value of Series A Exchange Warrant issuable to Platinum recorded as a Warrant Liability			(3,068,200)				(3,068,200)
Proceeds allocated to beneficial conversion feature of Investment Notes issued to Platinum in October 2012, February 2013 and March 2013			958,500				958,500
Incremental fair value of warrant modifications in Feburary 2013			67,500				67,500
Net Loss						(12,886,700)	(12,886,700)
Ending Balance, Amount at Mar. 31, 2013	500	23,500	59,266,000	(3,968,100)	(209,100)	(67,669,200)	(12,556,400)
Ending Balance, Shares at Mar. 31, 2013	500,000	23,480,169
Sale of common stock for cash, Amount		700	335,200				335,900
Sale of common stock for cash, Shares		655,106
Beneficial conversion feature on note			100,700				100,700
Share-based compensation expense			1,137,300				1,137,300
Payments on note receivable for sale of stock					11,000		11,000
Allocated proceeds from Sale of Units, amount			36,000				36,000
Allocated proceeds from Sale of Units, shares		50,000
Incremental value of warrant modifications (including modification of Platinum warrants)			204,300				204,300
Fair value of warrants issued to Morrison & Foerster, Cato Reearch Ltd. and University Health Network in connection with accrued interest on underlying notes			60,800				60,800
Net Loss						(2,967,700)	(2,967,700)
Ending Balance, Amount at Mar. 31, 2014	$ 500	$ 26,200	$ 61,976,500	$ (3,968,100)	$ (198,100)	$ (70,636,900)	$ (12,799,900)
Ending Balance, Shares at Mar. 31, 2014	500,000	26,200,185